In previous studies, MKC-1 demonstrated broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models.
Results from the preclinical studies demonstrated that MKC-1 showed significant antitumor activity as both a single agent and in combination with the cancer drug Tarceva. MKC-1 showed activity in both non-small cell lung cancer (NSCLC) and pancreatic cancer models. Tarceva is approved for the treatment of NSCLC. MKC-1 in combination with Tarceva was well tolerated and resulted in an additive antitumor response in preclinical models.
“These data represent continued progress with our MKC-1 program and provide further support for a phase II clinical trial with MKC-1 in pancreatic cancer. MKC-1 has shown tumor responses in previous clinical trials for breast cancer and NSCLC. MKC-1 is currently in phase II trials for metastatic breast cancer and non-small cell lung cancer, as well as a phase I clinical trial for leukemia,” commented Carolyn Sidor, EntreMed vice president.